Te-Din Huang
Te-Din Huang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Corentin Deckers
UCLouvain Medical School
3 shared publications - Pierre Bogaerts
Laboratory of clinical microbiology, National reference center for monitoring antimicrobial resistance in Gram-negative bacteria, CHU UCL Namur, Yvoir, Belgium
3 shared publications - Imane Saad Albichr
Laboratory Medicine—Microbiology, CHU UCL Namur, 5530 Yvoir, Belgium
2 shared publications - Isabel Montesinos
Microbiology Department, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, 1200 Brussels, Belgium
2 shared publications - Patrick M. Honore
ICU Department, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium
2 shared publications - Pierre Bulpa
ICU, CHU UCL Godinne Namur, UCL Louvain Medical School, 5530 Yvoir, Belgium
2 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Microbiology Society in Microbial Genomics
- Vol. 12 (10) , 001858
Genomic global epidemiology and evolution of Escherichia coli ST131 clade A
During the 2010s, Escherichia coli ST131 clade A tested sensitive to most antibiotics. In the 2020s, Europe experienced outbreaks of fluoroquinolone-resistant ST131-A that contained CTX-M β-lactamases and OXA-48-like carbapenemases. We investigated the acquisition of different antimicrobial resistance determinants in the emergence of multidrug-resistant (MDR) ST131-A. Phylogenetic analysis and Bayesian inference were utilized to define subclades and clusters (within subclades) and investigate the evolutionary history of ST131-A, using sequenced genomes and publicly available genomic data ( n =2,905). ST131-A consisted of five dominant subclades and ten frequent clusters, representing 93 and 83% of the total population, respectively. The sampled most recent common ancestors of the dominant subclades dated mainly to the 1990s. Several MDR clusters linked with diverse quinolone resistance-determining region mutations, CTX-M and OXA-48-like genes diversified during the 2000s. The distribution and mobile genetic elements linked with bla CTX-M-14 , bla CTX-M-15 and bla CTX-M-27 differed among ST131-A subclades and clusters across geographic locations. Three ST131-A clusters belonging to different subclades and carrying bla OXA-48 and bla OXA-244 in distinct genetic contexts were associated with the recent European dissemination. The identification of MDR ST131-A subclades and clusters with divergent molecular architectures emerging independently across regions highlights the challenges for public health surveillance and control efforts.
- 7 October 2026
- Published by Microbiology Society in Microbial Genomics
- Vol. 12 (10) , 001858
Open AccessGenomic global epidemiology and evolution of Escherichia coli ST131 clade A
During the 2010s, Escherichia coli ST131 clade A tested sensitive to most antibiotics. In the 2020s, Europe experienced outbreaks of fluoroquinolone-resistant ST131-A that contained CTX-M β-lactamases and OXA-48-like carbapenemases. We investigated the acquisition of different antimicrobial resistance determinants in the emergence of multidrug-resistant (MDR) ST131-A. Phylogenetic analysis and Bayesian inference were utilized to define subclades and clusters (within subclades) and investigate the evolutionary history of ST131-A, using sequenced genomes and publicly available genomic data ( n =2,905). ST131-A consisted of five dominant subclades and ten frequent clusters, representing 93 and 83% of the total population, respectively. The sampled most recent common ancestors of the dominant subclades dated mainly to the 1990s. Several MDR clusters linked with diverse quinolone resistance-determining region mutations, CTX-M and OXA-48-like genes diversified during the 2000s. The distribution and mobile genetic elements linked with bla CTX-M-14 , bla CTX-M-15 and bla CTX-M-27 differed among ST131-A subclades and clusters across geographic locations. Three ST131-A clusters belonging to different subclades and carrying bla OXA-48 and bla OXA-244 in distinct genetic contexts were associated with the recent European dissemination. The identification of MDR ST131-A subclades and clusters with divergent molecular architectures emerging independently across regions highlights the challenges for public health surveillance and control efforts.
- Open Access
- 15 March 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (3) , 224
Evaluation of Serum Biomarkers for Improved Diagnosis of Candidemia
Background: Candidemia, associated with high morbidity and mortality, remains challenging to diagnose due to the limitations of blood cultures. Serological biomarkers offer faster detection, enabling earlier treatment and improving outcomes. Methods: This study, conducted at CHU UCL Namur (August 2023–January 2025), evaluated three diagnostic biomarkers for candidemia: CAGTA IgG VirClia Monotest, Wako β-D-glucan test, and CandId OLM RT-PCR. A total of 35 candidemia cases and 20 controls were included. Results: CAGTA IgG VirClia Monotest demonstrated low sensitivity (46%) and moderate specificity (75%). Both Wako β-D-glucan test and CandId OLM RT-PCR exhibited higher sensitivity (74% and 71%, respectively) and excellent specificity (100%). The combined use of Wako β-D-glucan test and CandId OLM RT-PCR further enhanced diagnostic performance, achieving 91% sensitivity and 100% specificity. Misidentification between Candida albicans and Candida dubliniensis was observed with CandId PCR, underlining a potential limitation in species-level discrimination. Conclusions: Both Wako β-D-glucan test and CandID OLM RT-PCR outperformed CAGTA IgG VirClia Monotest in diagnosing candidemia, and their combination significantly improved diagnostic accuracy, albeit at a higher cost. These findings highlight the potential of integrating multiple biomarkers into diagnostic workflows to optimize early detection, though further studies are needed to refine strategies and address challenges.
- 15 March 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (3) , 224
Open AccessEvaluation of Serum Biomarkers for Improved Diagnosis of Candidemia
Background: Candidemia, associated with high morbidity and mortality, remains challenging to diagnose due to the limitations of blood cultures. Serological biomarkers offer faster detection, enabling earlier treatment and improving outcomes. Methods: This study, conducted at CHU UCL Namur (August 2023–January 2025), evaluated three diagnostic biomarkers for candidemia: CAGTA IgG VirClia Monotest, Wako β-D-glucan test, and CandId OLM RT-PCR. A total of 35 candidemia cases and 20 controls were included. Results: CAGTA IgG VirClia Monotest demonstrated low sensitivity (46%) and moderate specificity (75%). Both Wako β-D-glucan test and CandId OLM RT-PCR exhibited higher sensitivity (74% and 71%, respectively) and excellent specificity (100%). The combined use of Wako β-D-glucan test and CandId OLM RT-PCR further enhanced diagnostic performance, achieving 91% sensitivity and 100% specificity. Misidentification between Candida albicans and Candida dubliniensis was observed with CandId PCR, underlining a potential limitation in species-level discrimination. Conclusions: Both Wako β-D-glucan test and CandID OLM RT-PCR outperformed CAGTA IgG VirClia Monotest in diagnosing candidemia, and their combination significantly improved diagnostic accuracy, albeit at a higher cost. These findings highlight the potential of integrating multiple biomarkers into diagnostic workflows to optimize early detection, though further studies are needed to refine strategies and address challenges.
- Open Access
- 20 September 2024
- Published by MDPI AG in Journal of Fungi
- Vol. 10 (9) , 661
Diagnostic Value of Serum Biomarkers for Invasive Aspergillosis in Haematologic Patients
Background: Invasive aspergillosis (IA) is a significant cause of morbidity and mortality in patients with haematological malignancies. Accurate diagnosis of IA is challenging due to non-specific symptoms and the impact of antifungal prophylaxis on biomarker sensitivity. Methods: This retrospective study evaluated the diagnostic performance of three serum biomarkers: Aspergillus Galactomannan Ag VirClia Monotest® (VirClia), Wako β-D-Glucan Test® (Wako BDG), and MycoGENIE Real-Time PCR® (MycoGENIE PCR). True positives were defined as patients with proven or probable IA (n = 14), with a positive Platelia Aspergillus Antigen® (Platelia) serving as a mycological criterion. True negatives were identified as patients with a positive Platelia assay but classified as non-probable IA (n = 10) and outpatients who consistently tested negative with the Platelia test throughout the study period (n = 20). Results: Most patients diagnosed with proven or probable IA were acute myeloid leukaemia or myelodysplastic syndrome patients receiving mould-active antifungal prophylaxis or treatment (71%). VirClia demonstrated high sensitivity (100%) for detecting IA, with a specificity of 83%. Wako BDG and MycoGENIE PCR showed lower sensitivities for IA (57% and 64%, respectively). MycoGENIE PCR detected Aspergillus spp. and Mucorales in two patients. Conclusions: Accurate diagnosis of IA remains challenging, especially in patients who have received mould-active antifungal treatment. VirClia showed comparable performance to Platelia, suggesting its potential for routine use. However, Wako BDG and MycoGENIE PCR results were less favourable in our study cohort. Nevertheless, MycoGENIE PCR detected two probable co-infections with Aspergillus spp. and Mucorales.
- 20 September 2024
- Published by MDPI AG in Journal of Fungi
- Vol. 10 (9) , 661
Open AccessDiagnostic Value of Serum Biomarkers for Invasive Aspergillosis in Haematologic Patients
Background: Invasive aspergillosis (IA) is a significant cause of morbidity and mortality in patients with haematological malignancies. Accurate diagnosis of IA is challenging due to non-specific symptoms and the impact of antifungal prophylaxis on biomarker sensitivity. Methods: This retrospective study evaluated the diagnostic performance of three serum biomarkers: Aspergillus Galactomannan Ag VirClia Monotest® (VirClia), Wako β-D-Glucan Test® (Wako BDG), and MycoGENIE Real-Time PCR® (MycoGENIE PCR). True positives were defined as patients with proven or probable IA (n = 14), with a positive Platelia Aspergillus Antigen® (Platelia) serving as a mycological criterion. True negatives were identified as patients with a positive Platelia assay but classified as non-probable IA (n = 10) and outpatients who consistently tested negative with the Platelia test throughout the study period (n = 20). Results: Most patients diagnosed with proven or probable IA were acute myeloid leukaemia or myelodysplastic syndrome patients receiving mould-active antifungal prophylaxis or treatment (71%). VirClia demonstrated high sensitivity (100%) for detecting IA, with a specificity of 83%. Wako BDG and MycoGENIE PCR showed lower sensitivities for IA (57% and 64%, respectively). MycoGENIE PCR detected Aspergillus spp. and Mucorales in two patients. Conclusions: Accurate diagnosis of IA remains challenging, especially in patients who have received mould-active antifungal treatment. VirClia showed comparable performance to Platelia, suggesting its potential for routine use. However, Wako BDG and MycoGENIE PCR results were less favourable in our study cohort. Nevertheless, MycoGENIE PCR detected two probable co-infections with Aspergillus spp. and Mucorales.
- Open Access
- 10 January 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 28, 125-129
Multicentre interlaboratory analysis of routine susceptibility testing with a challenge panel of resistant strains
- 10 January 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 28, 125-129
Open AccessMulticentre interlaboratory analysis of routine susceptibility testing with a challenge panel of resistant strains